Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281523 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT05281523 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 264 participants.
The verdict
NCT05281523, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
Interventions
- DRUG Placebo
- BIOLOGICAL Depemokimab (GSK3511294)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281523
The ClinicalTrials.gov registry entry for NCT05281523 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05281523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05281523 about?
NCT05281523 is a clinical study titled "Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)". This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
What is the current status of trial NCT05281523?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2022-04-18. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT05281523?
The interventions under investigation include: Placebo (DRUG), Depemokimab (GSK3511294) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05281523?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.